Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) is a publicly traded Healthcare sector company. As of July 5, 2026, AMRX trades at $17.15 with a market cap of $5.48B and a P/E ratio of 43.97. AMRX moved +1.12% today. Year to date, AMRX is +33.15%; over the trailing twelve months it is +104.90%. Its 52-week range spans $6.69 to $17.86. Analyst consensus is strong buy with an average price target of $16.67. Rallies surfaces AMRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks hedge fund and 13F ownership for AMRX, including fund holders, share counts, and position changes when data is available.
| Metric | Value |
|---|---|
| Price | $17.15 |
| Market Cap | $5.48B |
| P/E Ratio | 43.97 |
| EPS | $0.39 |
| Dividend Yield | 0.00% |
| 52-Week High | $17.86 |
| 52-Week Low | $6.69 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $3.05B |
| Net Income | $181.31M |
| Gross Margin | 38.66% |
5 analysts cover AMRX: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $16.67.